Rohtak News Magazine

Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Analysis By DelveInsight

 Breaking News
  • No posts were found

Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Analysis By DelveInsight

September 04
19:04 2020
Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Diffuse Large B-Cell Lymphoma Market

 

DelveInsight’s ” Diffuse Large B-cell Lymphoma  Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Diffuse Large B-cell Lymphoma market report provides current treatment practices, emerging drugs, Diffuse Large B-cell Lymphoma market share of the individual therapies, current and forecasted Diffuse Large B-cell Lymphoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Diffuse Large B-cell Lymphoma (DLBCL) is “a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte.” DLBCL is a heterogeneous entity that includes a number of different variants and subtypes, with the current interest in identifying additional prognostically meaningful subsets. It occurs in young adults around age 35 and it affects slightly more women than men. Diffuse large B-cell lymphoma grows rapidly in the lymph nodes and frequently involves the spleen, liver, bone marrow or other organs. Usually, DLBCL development starts in lymph nodes in the neck or abdomen and is characterized by masses of large B cells. The most common symptom is painless swelling in the neck, armpit or groin. Other symptoms may include: tiredness, weight loss, night sweats and High temperatures (fevers).  In 2016’s WHO updated classification, DLBCL is divided in to following entities, DLBCL, NOS (not otherwise specified); DLBCL subtypes (such as, T-cell/histiocyte-rich Large B-cell Lymphoma; Primary DLBCL of the central nervous system; Primary cutaneous DLBCL, leg type; EBV positive DLBCL, NOS) and Other lymphomas of large B-cells. According to the Lymphoma Research Foundation, the occurrence of DLBCL generally increases with age, and most patients are over the age of 60 at diagnosis. It is more prevalent in male as compared to female.

 

View Free Sample Page:-  https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

 

Diffuse Large B-Cell Lymphoma Treatment

The therapeutic market of Diffuse Large B-cell Lymphoma includes conventional treatment options such as cytotoxic chemotherapeutics (Doxorubicin; Cyclophosphamide; Vincristine and Prednisone) (CHOP) and monoclonal antibody Rituximab (R) which are used as first-line treatment in patients with DLBCL Although R-CHOP is the standard regimen for diffuse large B-cell lymphoma, especially in patients with the germinal center B-cell (GCB) subtype, yet one-third of patients relapse after this therapy. In case of relapsed and refractory cases or higher stages, CAR-T therapies and other treatment modalities are recommended.

 

Diffuse Large B-Cell Lymphoma Market

There are not many options for the patients with DLBCL who relapse following first-line therapy. While some of the progress is made in the treatment of DLBCL but the area required more efforts for the potential treatment of this indication. Currently the researchers are working on several pharmacological treatment options for the same. In July 2019, the US Food and Drug Administration (FDA) granted accelerated approval to Polivy in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with DLBCL that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. “Antibody-drug conjugates” are an emerging class of targeted immunotherapies for cancer. This type of therapy, unlike traditional chemotherapy, is intended to target specific cells.

 

Diffuse Large B-Cell Lymphoma Report Scope

  • The report covers the descriptive overview of Diffuse Large B-cell Lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Diffuse Large B-cell Lymphoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Diffuse Large B-cell Lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Diffuse Large B-cell Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diffuse Large B-cell Lymphoma market

 

Download free sample page: – https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

 

Table of content

1. Key Insights

2. Executive Summary of Diffuse Large B-cell Lymphoma

3. Competitive Intelligence Analysis for Diffuse Large B-cell Lymphoma

4. Diffuse Large B-cell Lymphoma: Market Overview at a Glance

5. Diffuse Large B-cell Lymphoma: Disease Background and Overview

6. Patient Journey

7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment

11. Marketed Products

12. Emerging Therapies

13. Diffuse Large B-cell Lymphoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Diffuse Large B-cell Lymphoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Diffuse Large B-cell Lymphoma market
  • To understand the future market competition in the Diffuse Large B-cell Lymphoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Diffuse Large B-cell Lymphoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Diffuse Large B-cell Lymphoma market
  • To understand the future market competition in the Diffuse Large B-cell Lymphoma market

 

Related Reports

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles